Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both ...

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Q2 2025 Earnings Call Transcript July 31, 2025 Teleflex Incorporated misses on earnings expectations. Reported EPS is $2.77 EPS, expectations were $3.36. Operator: Good morning, ladies and gentlemen, ...

A new report in Open Forum Infectious Diseases details the significant increase of the Babesia season in New England since ...

Replimune (REPL) stock plummets as report suggests FDA’s top regulator of cancer drugs intervened in rejecting its lead asset ...

Wealth Enhancement reports that vacation homes are reshaping U.S. real estate, with over 6 million second homes concentrated ...

Fresenius Kabi has licensed rights from Polpharma Biologics to commercialize the vedolizumab biosimilar candidate PB016 globally—except in the ...